Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
A high index level often signals stronger market momentum or potential overbought conditions. Grasp its implications to adjust exposure and risk.
25,612 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
MIT economist and public thinker Daron Acemoglu argues AI's productivity gains will be modest in the near term, while...
Regulators opened a public comment period to redefine how crypto perpetual futures are labeled, a move that could res...
Tech-led optimism lifts the Nasdaq Composite as oil prices retreat. Traders weigh the Fed path and AI earnings signal...
Treat your finances like a health reset. This article delivers four practical tips going financial cleanse to curb sp...
Two popular ETFs divide energy exposure: XOP tracks producers, while OIH tracks oil services. This piece breaks down ...
A growing number of Americans are eyeing early retirement in The Villages, Florida, with a $3,000 monthly budget if t...
GameStop’s walking away from a massive pay package marks a dramatic pivot as the company uses its stock to press a bi...
As discounts surge through the warm months, shoppers and investors gain a rare window to save on essentials and stake...
Solstice and TensorX unveil a financing pact to fund up to $1 billion in European sovereign AI infrastructure, using ...
A top economist contends inflation is nearing a turning point, with a single gauge guiding bond yields and mortgage c...
Ripple's chief executive pushes back on BTC-focused tactics, praising XRP's utility. The remarks come as Strategy's S...